---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-040396"
form_type: "8-K"
ticker: "TECX"
cik: "0001681087"
company_name: "Tectonic Therapeutic, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:56:30.990687+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AVROBIO Q3 net loss narrows to $23M; cash runway into Q1 2024; Gaucher update Dec. 7

## Summary
- Net loss of $23.0M vs $32.6M in Q3 2021; R&D expenses fell to $15.9M from $23.0M.
- Cash and equivalents $116.0M as of Sept. 30, 2022, expected to fund operations into Q1 2024.
- Received rare pediatric disease designation for AVR-RD-02 (Gaucher) and AVR-RD-04 (cystinosis) from FDA.
- Patient dosing completed in collaborator-sponsored Phase 1/2 cystinosis trial; interim data show systemic effect.
- Investor update on Gaucher disease program scheduled for Dec. 7, 2022.

## SEC filing metadata
- accession: 0001140361-22-040396
- form_type: 8-K
- ticker: TECX
- cik: 0001681087
- company_name: Tectonic Therapeutic, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681087/000114036122040396/0001140361-22-040396-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681087/000114036122040396/ny20005640x2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-040396
- JSON: https://secwatch.observer/filing/0001140361-22-040396.json
- Plain text: https://secwatch.observer/filing/0001140361-22-040396.txt

## Key facts
- Earnings Releases
  Tectonic Therapeutic, Inc. reported three and nine months ended September 30, 2022 results: net income $23.0 million.
  - Period: three and nine months ended September 30, 2022
  - Net income: $23.0 million
  - Result: reported results
  source text: On November 8, 2022, AVROBIO, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations for the three and nine months ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1681087/000114036122040396/0001140361-22-040396-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.